{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04599478",
            "orgStudyIdInfo": {
                "id": "2000029057"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DK126637-01",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DK126637-01"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)",
            "officialTitle": "Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Acute (Stage 1)",
            "therapeuticArea": [
                "Endocrinology",
                "Other"
            ],
            "study": "pharmacological-and-behavioral-treatment-after-bariatric-surgery-acute-stage"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-10-21",
            "studyFirstSubmitQcDate": "2020-10-21",
            "studyFirstPostDateStruct": {
                "date": "2020-10-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study will compare the effectiveness of behavioral and pharmacologic treatments, alone and in combination, for the treatment of loss-of-control eating and weight following bariatric surgery. This is an acute treatment comparing behavioral weight loss alone or in combination with combination naltrexone/bupropion medication.",
            "detailedDescription": "Participants who provide informed consent and are determined to be eligible will then participate in the study.\n\nA total of 160 patients with obesity and regular LOC-eating following MBS will be randomly assigned (double-blind) in a balanced factorial (2 X 2) design, to one of four 16-week interventions: BWL+NB, BWL+Placebo, NB, or Placebo. The randomization will be in equal proportions but stratified by surgery type."
        },
        "conditionsModule": {
            "conditions": [
                "Loss-of-control Eating",
                "Obesity/Overweight"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 160,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication",
                    "type": "EXPERIMENTAL",
                    "description": "Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.",
                    "interventionNames": [
                        "Drug: Naltrexone and Bupropion medication",
                        "Behavioral: Behavioral Weight Loss"
                    ]
                },
                {
                    "label": "BWL + Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants randomly assigned to this arm will receive 16 weeks of BWL counseling and placebo. Placebo will be inactive and taken daily in pill form.",
                    "interventionNames": [
                        "Behavioral: Behavioral Weight Loss",
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "NB medication",
                    "type": "EXPERIMENTAL",
                    "description": "Participants randomly assigned to this arm will receive 16 weeks of NB medication taken daily in pill form.",
                    "interventionNames": [
                        "Drug: Naltrexone and Bupropion medication"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Naltrexone and Bupropion medication",
                    "description": "NB medication will be taken daily in pill form.",
                    "armGroupLabels": [
                        "Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication",
                        "NB medication"
                    ],
                    "otherNames": [
                        "Contrave"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Behavioral Weight Loss",
                    "description": "Behavioral Weight Loss (BWL) counseling includes weekly sessions.",
                    "armGroupLabels": [
                        "BWL + Placebo",
                        "Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Placebo will be inactive and taken daily in pill form.",
                    "armGroupLabels": [
                        "BWL + Placebo",
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Loss-of-control Eating Frequency",
                    "description": "Loss-of-control eating frequency is a continuous variable of loss-of-control eating episodes assessed using the Eating Disorder Examination interview; Loss-of-control eating frequency will be based on the past 28 days and defined as loss-of-control eating episodes per month.",
                    "timeFrame": "Post-treatment (4 months)"
                },
                {
                    "measure": "Body Mass Index",
                    "description": "BMI is calculated using measured height and weight",
                    "timeFrame": "Post-treatment (4 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Loss-of-control Eating Remission",
                    "description": "Categorical: zero episodes/28 days",
                    "timeFrame": "Post-treatment (4 months)"
                },
                {
                    "measure": "Weight loss",
                    "description": "Categorical: 5% weight loss",
                    "timeFrame": "Post-treatment (4 months)"
                },
                {
                    "measure": "Eating Disorder Psychopathology",
                    "description": "Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).",
                    "timeFrame": "Post-treatment (4 months)"
                },
                {
                    "measure": "Depressive Symptoms",
                    "description": "Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Patient Health Questionnaire - 9. Scores range from 0-27 (0=no depressive symptoms, 27=greater depressive symptoms).",
                    "timeFrame": "Post-treatment (4 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Be in the age range \u226518 years of age and \u226470 years of age.\n* Have a BMI \u226530 (or BMI \u226527 with a medical comorbidity) and \u226450\n* Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy\n* Approximately six months post-surgery\n* Experience regular loss-of-control eating (defined as at least once weekly over the past 28 days)\n* Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).\n* Read, comprehend, and write English at a sufficient level to complete study-related materials.\n* Provide a signed and dated written informed consent prior to study participation.\n\nBe available for participation in the study for up to 19 months (7-month treatment plus 12-month follow up).\n\nExclusion Criteria:\n\n* Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).\n* Has a history of anorexia nervosa or history of bulimia nervosa.\n* Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).\n* Is currently using other medications for weight loss.\n* Has a history of allergy or sensitivity to bupropion or naltrexone.\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)\n* Has untreated hypertension with a seated systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg, or heart rate \\> 100 beats/minute.\n* Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.\n* Has current uncontrolled hypertension.\n* Has current uncontrolled Type I or Type II diabetes mellitus.\n* Has untreated hypothyroidism with a TSH \\> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.\n* Has gallbladder disease.\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.\n* Has a recent history of drug or alcohol dependence (since having bariatric surgery).\n* Is currently in active treatment for eating or weight loss.\n* Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.\n* Is breast-feeding or is pregnant or is not using a reliable form of birth control.\n* Reports active suicidal or homicidal ideation.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Valentina Ivezaj, Ph.D.",
                    "role": "CONTACT",
                    "phone": "203-785-7210",
                    "email": "valentina.ivezaj@yale.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Yale Department of Psychiatry",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06510",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Valentina Ivezaj, Ph.D.",
                            "role": "CONTACT",
                            "phone": "203-785-7210",
                            "email": "valentina.ivezaj@yale.edu"
                        },
                        {
                            "name": "Carlos M Grilo, Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000050177",
                    "term": "Overweight"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044343",
                    "term": "Overnutrition"
                },
                {
                    "id": "D000009748",
                    "term": "Nutrition Disorders"
                },
                {
                    "id": "D000001835",
                    "term": "Body Weight"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5114",
                    "name": "Body Weight",
                    "relevance": "LOW"
                },
                {
                    "id": "M12701",
                    "name": "Obesity",
                    "relevance": "LOW"
                },
                {
                    "id": "M26186",
                    "name": "Overweight",
                    "asFound": "Overweight",
                    "relevance": "HIGH"
                },
                {
                    "id": "M25307",
                    "name": "Overnutrition",
                    "relevance": "LOW"
                },
                {
                    "id": "M12684",
                    "name": "Nutrition Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009271",
                    "term": "Naltrexone"
                },
                {
                    "id": "D000016642",
                    "term": "Bupropion"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000427",
                    "term": "Alcohol Deterrents"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000018687",
                    "term": "Antidepressive Agents, Second-Generation"
                },
                {
                    "id": "D000000928",
                    "term": "Antidepressive Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018765",
                    "term": "Dopamine Uptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000015259",
                    "term": "Dopamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000065690",
                    "term": "Cytochrome P-450 CYP2D6 Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12222",
                    "name": "Naltrexone",
                    "asFound": "Closure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19013",
                    "name": "Bupropion",
                    "asFound": "Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3777",
                    "name": "Ethanol",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M4247",
                    "name": "Antidepressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M7473",
                    "name": "Dopamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M20832",
                    "name": "Dopamine Uptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M17962",
                    "name": "Dopamine Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AlcDet",
                    "name": "Alcohol Deterrents"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CaAg",
                    "name": "Cardiotonic Agents"
                }
            ]
        }
    },
    "hasResults": false
}